Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Adam Scott Levy, Chief Financial Officer and Secretary of Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company with a market capitalization of approximately $979 million, sold 10,758 shares of common stock on July 11, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The company’s stock has shown strong momentum, delivering a 52.8% return over the past six months. The shares were sold at a weighted-average price of $14.4501, for a total value of $155454.
The sales were executed in multiple transactions at prices ranging from $14.3012 to $14.6546. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. Following the transaction, Levy directly owns 206,612 shares of Mineralys Therapeutics. This balance includes 2,030 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.According to InvestingPro, Mineralys maintains a strong liquidity position with more cash than debt, while analysts have set price targets ranging from $15 to $48 per share. Get access to 10+ additional ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, Mineralys Therapeutics, Inc. announced positive results from its Phase 3 Launch-HTN trial for lorundrostat, showing significant reductions in systolic blood pressure for patients with uncontrolled or treatment-resistant hypertension. The trial, involving 1,083 participants, demonstrated a 19.0 mmHg reduction at week 12, with results published in the Journal of the American Medical (TASE:BLWV) Association. Additionally, Mineralys reported favorable outcomes from its Phase 2 Explore-CKD trial, which met its primary endpoint with a 7.5 mmHg placebo-adjusted reduction in systolic blood pressure and a 25.6% reduction in urine albumin-to-creatinine ratio. H.C. Wainwright reiterated a Buy rating with a $42.00 price target following these results, citing potential for a robust NDA submission. Meanwhile, Jefferies maintained a Hold rating and $15.00 price target, noting limited catalysts for Mineralys in the next 12-18 months but acknowledging the company’s interest in finding commercial partners. Mineralys plans to discuss the regulatory pathway with the FDA in late 2025, as it continues to develop lorundrostat for various conditions. The company reported having $343 million cash at the end of Q1 2025, with a quarterly burn rate of $30-40 million, indicating a need for additional financing before its anticipated U.S. launch in H1 2027. These developments highlight Mineralys’s ongoing efforts and strategic planning in the pharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.